LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, announced strong unaudited preliminary results for the second quarter ended July 3, 2026, with net sales for 2026 expected to exceed $90 million, compared with the $44.3 million recorded in same period of 2025. This follows the company’s report in May of record first-quarter net sales of $93.5 million, up 119.6 percent from $42.6 million in the prior-year period.
“We are pleased to report that we expect second quarter net sales to be in excess of $90 million, reflecting the strength of our team’s execution and the diversity of our global commercial operations,” said Warren Foust, co-CEO, president and chief operating officer. “While geopolitical and macroeconomic pressures continue to present headwinds in certain markets, and while our ERP system implementation presented meaningful operational challenges during the quarter, our team again rose to the occasion and delivered strong results. We remain focused on resolving the remaining system issues in the third quarter and are confident in the continued momentum of our business.”
The company attributed the strong results to sequential growth in China, solid progress across the broader Asia-Pacific region, and double-digit growth in the Americas. In the EMEA region, net sales declined by a low single-digit percentage, reflecting ongoing turmoil in the Middle East, the company posited; however, excluding the Middle East, EMEA achieved double-digit percentage growth, underscoring the strength of the company’s underlying business across that region.
Net sales in the Middle East, as well as certain parts of the EMEA and Asia-Pacific regions, continued to be adversely affected by significant geopolitical and macroeconomic headwinds, the company noted, resulting in sales declines in those areas. The company advised that it is “actively monitoring” these conditions and cautions that, if the current headwinds persist or worsen, sales growth could continue to be negatively affected. Furthermore, the company noted that a broadening of macroeconomic challenges to additional regions also could affect future results.
By the conclusion of the second quarter of 2026, distributor inventory has aligned with its targeted range to effectively support the refractive market, the company stated. This stabilization follows a decline in net sales during the second quarter of 2025, which occurred when shipments of EVO ICLs to China were minimized while distributors cleared surplus inventory.
“Our three core strategic objectives for 2026 continue to be revenue growth, profit expansion, and innovation acceleration,” said Foust. “We look forward to providing additional perspective on progress regarding these goals when we report our full second quarter results.”
In February of this year, the company announced that the U.S. Food and Drug Administration (FDA) approved an expanded age indication for EVO/EVO+ Visian ICL for patients aged 21 to 60 years old, up from the previous approval for ages 21-45. This announcement came approximately one month after STAAR Surgical and Alcon terminated a merger agreement by which Alcon intended to acquire STAAR.
STAAR Surgical disclosed that it will release its official quarterly earnings report on August 12, 2026.
